Psychedelics & Empathogens in 2026
Psilocybin for AUD. Ibogaine for OUD. MDMA's setback. What the clinical trial landscape actually shows.
Body — 8 lenses: [Science: 5-HT2A agonism (classical psychedelics), MDMA serotonin/dopamine/NE release, ibogaine multi-receptor (anti-addiction window). Biology: acute autonomic effects, serotonin syndrome risk in combos, ibogaine cardiac risk (QT prolongation — real, requires screening), HPPD rare but possible. Psychology: “mystical experience” correlating with therapeutic outcome (Griffiths et al.); challenging experiences and how they’re handled in set/setting. Policy: mostly Schedule I; Oregon Measure 109, Colorado Prop 122, FDA breakthrough designations; MDMA 2024 rejection; state-level initiatives for decrim/regulated access. Trends: psychedelic clinic growth (often off-label ketamine), “microdosing” research (mostly null), ayahuasca tourism. Social: counterculture roots → medicalization → commercialization tension; indigenous reciprocity conversation. Treatment: psilocybin+therapy for AUD (NYU + Hopkins RCTs); ibogaine for OUD (Stanford case series, Kentucky state research); MDMA-AT for PTSD (post-2024 setback, new trials). Harm reduction: set/setting, integration, contraindications (SSRIs, heart conditions, family psychosis history for classical psychedelics), test kits.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
- 03.B
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Getting High With Friends Is the Riskier Choice — If You Already Have a Problem
A September 2026 Addiction study of 104 adults found that using cannabis around other people amplifies craving and continued use, but only for those with more severe cannabis problems.
Science & MedicineThe Craving Doesn't Expire on Your Sobriety Anniversary
New EEG and animal studies show heroin cravings can be measured in the brain and persist more than a year into abstinence, challenging fixed-length treatment models.
Science & MedicineNitrous Oxide Deaths Rose Nearly 600% While Regulators Treated Galaxy Gas Like a Whipped-Cream Ingredient
A JAMA Network Open study of CDC data found US nitrous oxide deaths rose from 23 to 156 a year between 2010-2023. Researchers tie the spike to culinary-labeled brands like Galaxy Gas exploiting a regulatory gap.